Association between cytokines and methylation of SOCS-1 in serum of patients with ankylosing spondylitis

Molecular Biology Reports

Volumn 41, Issue 6, 2014, Pages 3773-3780

  Lai, Ning Sheng ^a,b   Chou, Jian Liang ^c   Chen, Gary C W ^c   Liu, Su Qin ^a,b   Lu, Ming Chi ^a,b   Chan, Michael W Y ^c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Ankylosing spondylitis; Epigenetics; SOCS 1 methylation

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CYTOKINE; DNA; HLA B27 ANTIGEN; INTERLEUKIN 6; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR NECROSIS FACTOR ALPHA; SOCS1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; METHYLATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SACROILIITIS; VERY ELDERLY; BLOOD; DNA METHYLATION; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GENETICS; INFLAMMATION; MIDDLE AGED; PATHOLOGY; PROMOTER REGION;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; SPONDYLITIS, ANKYLOSING; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902379225     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3242-2     Document Type: Article

References (45)

1. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G et al (1991) The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218-1227
2. Khan MA, van der Linden SM (1990) Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am 16:551-579 (Pubitemid 20330586)
3. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD (1973) Ankylosing spondylitis and HL-A 27. Lancet 1:904-907
4. van der Linden SM, Valkenburg HA, de Jongh BM, Cats A (1984) The risk of developing ankylosing spondylitis in HLAB27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 27:241-249 (Pubitemid 14163215)
5. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, Molina R, Ballesta A, Munoz-Gomez J (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927-931 (Pubitemid 24324807)
6. Tutuncu ZN, Bilgie A, Kennedy LG, Calin A (1994) Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis 53:425-426 (Pubitemid 24198933)
7. Grom AA, Murray KJ, Luyrink L, Emery H, Passo MH, Glass DN, Bowlin T, Edwards C 3rd (1996) Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum 39:1703-1710 (Pubitemid 26331024)
8. Canete JD, Llena J, Collado A, Sanmarti R, Gaya A, Gratacos J, Blay M, Munoz-Gomez J (1997) Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 36:38-42
9. Chan MW, Huang YW, Hartman-Frey C, Kuo CT, Deatherage D, Qin H, Cheng AS, Yan PS, Davuluri RV, Huang TH, Nephew KP, Lin HJ (2008) Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia 10:908-919
10. Zuo T, Liu TM, Lan X, Weng YI, Shen R, Gu F, Huang YW, Liyanarachchi S, Deatherage DE, Hsu PY, Taslim C, Ramaswamy B, Shapiro CL, Lin HJ, Cheng AS, Jin VX, Huang TH (2011) Epigenetic silencing mediated through activated PI3K/ AKT signaling in breast cancer. Cancer Res 71:1752-1762
11. Papageorgis P, Lambert AW, Ozturk S, Gao F, Pan H, Manne U, Alekseyev YO, Thiagalingam A, Abdolmaleky HM, Lenburg M, Thiagalingam S (2010) Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res 70:968-978
12. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome: biological and translational implications. Nat Rev Cancer 11:726-734
13. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692 (Pubitemid 46273572)
14. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB (1995) Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530
15. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5 0 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686-692
16. Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229 (Pubitemid 32695003)
17. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM, To KF (2002) Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8:464-470 (Pubitemid 34193966)
18. Chou JL, Su HY, Chen LY, Liao YP, Hartman-Frey C, Lai YH, Yang HW, Deatherage DE, Kuo CT, Huang YW, Yan PS, Hsiao SH, Tai CK, Lin HJ, Davuluri RV, Chao TK, Nephew KP, Huang TH, Lai HC, Chan MW (2010) Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 90:414-425
19. Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253-266
20. Chan MW, Chu ES, To KF, Leung WK (2004) Quantitative detection of methylated SOCS-1, a tumor suppressor gene, by a modified protocol of quantitative real time methylation-specific PCR using SYBR green and its use in early gastric cancer detection. Biotechnol Lett 26:1289-1293
21. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF (2002) Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8:1761-1766 (Pubitemid 34633732)
22. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M (2006) DNA methylation: bisulphite modification and analysis. Nat Protoc 1:2353-2364
23. Tseng KC, Chou JL, Huang HB, Tseng CW, Wu SF, Chan MW (2013) SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin. J Clin Immunol 33(6):1110-1116
24. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R (2003) Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 35:146-150 (Pubitemid 36828724)
25. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R (2007) Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNFalpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26:211-215 (Pubitemid 46020247)
26. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, Gutkind JS (2006) Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 8:733-746 (Pubitemid 44465525)
27. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS (2003) Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 163:1551-1556 (Pubitemid 37175101)
28. Kaneto H, Sasaki S, Yamamoto H, Itoh F, Toyota M, Suzuki H, Ozeki I, Iwata N, Ohmura T, Satoh T, Karino Y, Toyota J, Satoh M, Endo T, Omata M, Imai K (2001) Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 48:372-377 (Pubitemid 32269566)
29. Ballestar E (2011) Epigenetic alterations in autoimmune rheumatic diseases. Nat Rev Rheumatol 7:263-271
30. Baud V, Karin M (2001) Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11:372-377 (Pubitemid 32900529)
31. Nicola NA, Greenhalgh CJ (2000) The suppressors of cytokine signaling (SOCS) proteins: important feedback inhibitors of cytokine action. Exp Hematol 28:1105-1112
32. Chou JL, Chen LY, Lai HC, Chan MW (2010) TGF-beta: friend or foe? The role of TGF-beta/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy. Expert Opin Ther Targets 14:1213-1223
33. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA (2005) STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA 102:6948-6953 (Pubitemid 40675422)
34. To KF, Chan MW, Leung WK, Ng EK, Yu J, Bai AH, Lo AW, Chu SH, Tong JH, Lo KW, Sung JJ, Chan FK (2004) Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br J Cancer 91:1335-1341 (Pubitemid 39424795)
35. Tanabe K, Matsushima-Nishiwaki R, Yamaguchi S, Iida H, Dohi S, Kozawa O (2010) Mechanisms of tumor necrosis factor-alpha-induced interleukin-6 synthesis in glioma cells. J Neuroinflammation 7:16
36. Lu MC, Yang KL, Tung CH, Huang KY, Yu HC, Liu SQ, Lai NS (2008) Higher LPS-stimulated TNF-alpha mRNA levels in peripheral blood mononuclear cells from Chinese ankylosing spondylitis patients with -308G/A polymorphism in promoter region of tumor necrosis factor: association with distinct A33/ B58/Cw10 haplotypes. Rheumatol Int 29:189-195
37. Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369: 1379-1390 (Pubitemid 46590387)
38. Heiberg MS, Nordvag BY, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, Kvien TK (2005) The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a sixmonth, longitudinal, observational, multicenter study. Arthritis Rheum 52:2506-2512 (Pubitemid 41117438)
39. Shima Y, Tomita T, Ishii T, Morishima A, Maeda Y, Ogata A, Kishimoto T, Tanaka T (2011) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol 21:436-439
40. Vishwakarma S, Iyer LR, Muley M, Singh PK, Shastry A, Saxena A, Kulathingal J, Vijaykanth G, Raghul J, Rajesh N, Rathinasamy S, Kachhadia V, Kilambi N, Rajgopal S, Balasubramanian G, Narayanan S (2013) Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects. Int Immunopharmacol 16:72-78
41. Motegi K, Azuma M, Tamatani T, Ashida Y, Sato M (2005) Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza- 2′-deoxycytidine: a possibility for improvement of xerostomia in patients with Sjogren's syndrome. Lab Invest 85:342-353 (Pubitemid 40333151)
42. Bernatsky S, Ramsey-Goldman R, Clarke A (2006) Malignancy and autoimmunity. Curr Opin Rheumatol 18:129-134 (Pubitemid 43740384)
43. Au WY, Hawkins BR, Cheng N, Lie AK, Liang R, Kwong YL (2001) Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol 115:320-322 (Pubitemid 34203495)
44. Chiang CJ, Chen YC, Chen CJ, You SL, Lai MS (2010) Cancer trends in Taiwan. Jpn J Clin Oncol 40:897-904
45. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24:2225-2229 (Pubitemid 27474048)